John Nash joins BioFocus as Senior Director, ADME/PK
News Oct 01, 2009
John has 30 years industrial experience with both service and major pharmaceutical companies. Most recently, John worked for eight years for Charles River Laboratories in Quebec, Canada, where he was responsible for strengthening the DMPK service business, and making it a successful, revenue generating operation. Prior to moving to Canada, John worked in the UK with Anserve and AstraZeneca/Syngenta in metabolism and pharmacokinetics. John holds an M. Phil. degree from the University of Surrey and a Ph. D. degree from the University of Manchester.
“John Nash’s appointment is a major win for BioFocus in the UK,” commented Dr. Chris Newton, SVP BioFocus. “With this hire, BioFocus continues to elevate its 175 scientist facility at Chesterford Research Park into a leading integrated discovery research center for pharma, biotech and not-for-profit organizations worldwide.”
For further information, please visit www.biofocus.com.
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?READ MORE
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent painful swellings of the skin and mucous membranes. A new drug has been developed to help prevent attacks of hereditary angioedema. It has now been investigated in an international study performed at over 26 university facilities in Europe, Canada and Australia.READ MORE